Paradigm is building a new model for #clinicaltrials, from the ground up, using technology to scale access. Recently, we worked with OpenAI to evaluate GPT-4 to reduce the administrative burden of screening patients for clinical trials. Our team achieved amazing results, exceeding accuracy of industry best practice while dramatically decreasing the time to read, extract, and interpret medical record data. By incorporating LLMs into Paradigm’s platform, we can screen every patient faster, more accurately, and at a dramatically lower cost, helping create equitable access for any patient, anywhere. We are excited that OpenAI shared our results here: https://lnkd.in/eE5MYUzw
Congrats, and great use case for GPT 4!
exciting results- Jonathan Hirsch
Founder and CEO
6mo🔥